<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545272</url>
  </required_header>
  <id_info>
    <org_study_id>CQMF149A2201</org_study_id>
    <secondary_id>2007-003191-19</secondary_id>
    <nct_id>NCT00545272</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma</brief_title>
  <official_title>A Randomized, Multi-center, Parallel Group, Double Blind, Placebo and Formoterol Controlled 14 Day Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the dose response relationship among four doses of indacaterol as
      well as placebo delivered via the TWISTHALER® device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline (prior to first dose) and Day 15 (24 hours after last dose)</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 14 days of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose</measure>
    <time_frame>Day 14, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose.</time_frame>
    <description>FEV1 was measured on Day 14 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) on Day 1</measure>
    <time_frame>Day 1 Baseline (prior to first dose) and 24 hours post-dose.</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose on Day 1</measure>
    <time_frame>Day 1, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose.</time_frame>
    <description>FEV1 was measured on Day 1 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 14</measure>
    <time_frame>Day 1 and Day 14 measured pre-dose and up to 4 hours post-dose</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1, which is taken as the maximum FEV1 recorded post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning and Evening Peak Expiratory Flow</measure>
    <time_frame>Baseline (recorded during the screening period) and Days 1-14 (treatment period)</time_frame>
    <description>The Peak Expiratory Flow (PEF) rate is the maximal rate that a person can exhale during a short maximal expiratory effort after fully inhaling. Participants measured their PEF using a peak flow meter and recorded measurements in a diary every morning and evening during the study, prior to taking study medication. Change from baseline is the difference between the mean baseline PEF recorded during the screening period until the first day of treatment, and the overall mean PEF from Days 1 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Rescue Medication</measure>
    <time_frame>Over 14 days</time_frame>
    <description>Participants recorded the use of rescue medications (salbutamol/albuterol) for treatment of asthma symptoms twice a day in a diary during the 14 days of the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>indacaterol 62.5 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indacaterol 125 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indacaterol 250 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indacaterol 500 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indacaterol</intervention_name>
    <description>Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).</description>
    <arm_group_label>indacaterol 62.5 μg</arm_group_label>
    <arm_group_label>indacaterol 125 μg</arm_group_label>
    <arm_group_label>indacaterol 250 μg</arm_group_label>
    <arm_group_label>indacaterol 500 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol</intervention_name>
    <description>Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.</description>
    <arm_group_label>formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to indacaterol</intervention_name>
    <description>Placebo TWISTHALER® device</description>
    <arm_group_label>formoterol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to formoterol</intervention_name>
    <description>Placebo AEROLIZER® device</description>
    <arm_group_label>indacaterol 62.5 μg</arm_group_label>
    <arm_group_label>indacaterol 125 μg</arm_group_label>
    <arm_group_label>indacaterol 250 μg</arm_group_label>
    <arm_group_label>indacaterol 500 μg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>short acting β2-agonist</intervention_name>
    <description>100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).</description>
    <arm_group_label>indacaterol 62.5 μg</arm_group_label>
    <arm_group_label>indacaterol 125 μg</arm_group_label>
    <arm_group_label>indacaterol 250 μg</arm_group_label>
    <arm_group_label>indacaterol 500 μg</arm_group_label>
    <arm_group_label>formoterol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female adult and adolescent patients aged 12-75 years inclusive (or ≥18-75
             years depending upon regulatory and/or Institutional Review Board (IRB)/Independent
             Ethics Committee (IEC)/Research Ethics Board (REB) approval), who have signed an
             Informed Consent Form prior to initiation of any study-related procedure, including
             any adjustments to asthma medication prior to Visit 1. Patients below the legal age of
             consent are required to have the Informed Consent Form signed by the patient's parent
             / guardian.

          2. Patients with asthma, diagnosed according to Global Initiative for Asthma (GINA)
             guidelines (National Institute of Health, National Heart, Lung and Blood Institute,
             2006) and who additionally meet the following criteria:

               1. Patients receiving daily treatment with inhaled corticosteroid up to the maximum
                  dose per day indicated in the package leaflet, in a stable regimen for the month
                  prior to Visit 1.

               2. Patients with a Forced Expiratory Volume in one second (FEV1) at Visit 1 of ≥50%
                  of the predicted normal value for the patient. This criterion for FEV1 will have
                  to be demonstrated after a washout period of at least 6 hours during which no
                  short acting β2-agonist has been inhaled, and a minimum of 48 hours for a long
                  acting β2-agonist.

               3. Patients who demonstrate an increase of ≥12% and ≥200 mL in FEV1 over their
                  pre-bronchodilator value within 30 minutes after inhaling a total of 200 µg/180
                  µg of salbutamol/albuterol Metered Dose Inhaler (MDI) (or equivalent dose of Dry
                  Powder Inhaler [DPI]) (the reversibility test). Reversibility will have to be
                  demonstrated after an appropriate washout period of at least 6 hrs prior to the
                  evaluation for a short-acting β2-agonist. The administration of
                  salbutamol/albuterol for the reversibility test is to be within 30 minutes after
                  pre bronchodilator spirometry. Reversibility has to be demonstrated at Visit 1 or
                  between Visits 1 and 2, in order for patients to be included in the trial.

        Exclusion Criteria:

          -  Pregnant women, nursing mothers, or females of childbearing potential, regardless of
             whether or not sexually active, if they are not using a reliable form of
             contraception.

          -  Patients with Chronic Obstructive Pulmonary Disease (COPD), or current smokers, or
             patients who have used tobacco products within the 6 month period prior to Visit 1, or
             who have a smoking history of greater than 10 pack years.

          -  Patients:

               1. who's asthma is likely to deteriorate during the study (including seasonal
                  allergy),

               2. hospitalized for an acute asthma attack/asthma exacerbation within 6 months prior
                  to Visit 1,

               3. who have had an emergency room visit for an asthma attack/asthma exacerbation
                  within 6 weeks prior to Visit 1

               4. who have had a respiratory tract infection or emergency room treatment for an
                  asthma attack/asthma exacerbation within 4 weeks prior to Visit 1

               5. Patients who require the use of ≥8 inhalations per day of short acting B2-agonist
                  (100 µg/ 90 µg salbutamol/albuterol MDI or equivalent dose of DPI) on any 2
                  consecutive days from Screening to Randomization.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Halen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oostham</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Veurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Boskovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Breclav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Most</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Aalen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Deggendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Furstenwalde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>novartis Investigator site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigator site</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Erd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Fuzesabony</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gyonggyos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mosdoz</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Siofok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigator site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigator site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tel-Hashorner</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigator site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigator site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bloernfontain</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>les Marais</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Roodepoort</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Temba</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pozuelo de Alacron</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Downpatrick</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Watford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <results_first_submitted>November 12, 2012</results_first_submitted>
  <results_first_submitted_qc>December 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2013</results_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QMF</keyword>
  <keyword>indacaterol</keyword>
  <keyword>Twisthaler®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Indacaterol 62.5 μg</title>
          <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Indacaterol 125 μg</title>
          <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="P3">
          <title>Indacaterol 250 μg</title>
          <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>Indacaterol 500 μg</title>
          <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="P5">
          <title>Formoterol</title>
          <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="62"/>
                <participants group_id="P6" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indacaterol 62.5 μg</title>
          <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Indacaterol 125 μg</title>
          <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Indacaterol 250 μg</title>
          <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>Indacaterol 500 μg</title>
          <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="B5">
          <title>Formoterol</title>
          <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="72"/>
            <count group_id="B5" value="64"/>
            <count group_id="B6" value="62"/>
            <count group_id="B7" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="16.27"/>
                    <measurement group_id="B2" value="38.4" spread="17.25"/>
                    <measurement group_id="B3" value="36.6" spread="15.76"/>
                    <measurement group_id="B4" value="40.1" spread="15.47"/>
                    <measurement group_id="B5" value="44.0" spread="17.98"/>
                    <measurement group_id="B6" value="39.8" spread="15.82"/>
                    <measurement group_id="B7" value="40.0" spread="16.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 14 days of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.</description>
        <time_frame>Baseline (prior to first dose) and Day 15 (24 hours after last dose)</time_frame>
        <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 14 days of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.</description>
          <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.0408"/>
                    <measurement group_id="O2" value="0.054" spread="0.0383"/>
                    <measurement group_id="O3" value="0.124" spread="0.0401"/>
                    <measurement group_id="O4" value="0.166" spread="0.0381"/>
                    <measurement group_id="O5" value="0.075" spread="0.0405"/>
                    <measurement group_id="O6" value="-0.018" spread="0.0415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose</title>
        <description>FEV1 was measured on Day 14 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.</description>
        <time_frame>Day 14, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose.</time_frame>
        <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. Observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose</title>
          <description>FEV1 was measured on Day 14 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.</description>
          <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. Observed data only.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.670" spread="0.0419"/>
                    <measurement group_id="O2" value="2.698" spread="0.0400"/>
                    <measurement group_id="O3" value="2.772" spread="0.0411"/>
                    <measurement group_id="O4" value="2.786" spread="0.0393"/>
                    <measurement group_id="O5" value="2.821" spread="0.0418"/>
                    <measurement group_id="O6" value="2.565" spread="0.0426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) on Day 1</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.</description>
        <time_frame>Day 1 Baseline (prior to first dose) and 24 hours post-dose.</time_frame>
        <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) on Day 1</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.</description>
          <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.0347"/>
                    <measurement group_id="O2" value="0.081" spread="0.0326"/>
                    <measurement group_id="O3" value="0.143" spread="0.0339"/>
                    <measurement group_id="O4" value="0.141" spread="0.0326"/>
                    <measurement group_id="O5" value="0.155" spread="0.0341"/>
                    <measurement group_id="O6" value="0.010" spread="0.0344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose on Day 1</title>
        <description>FEV1 was measured on Day 1 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.</description>
        <time_frame>Day 1, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose.</time_frame>
        <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. Observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose on Day 1</title>
          <description>FEV1 was measured on Day 1 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.</description>
          <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. Observed data only.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.668" spread="0.0281"/>
                    <measurement group_id="O2" value="2.687" spread="0.0264"/>
                    <measurement group_id="O3" value="2.726" spread="0.0272"/>
                    <measurement group_id="O4" value="2.753" spread="0.0259"/>
                    <measurement group_id="O5" value="2.832" spread="0.0274"/>
                    <measurement group_id="O6" value="2.547" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 14</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1, which is taken as the maximum FEV1 recorded post-dose.</description>
        <time_frame>Day 1 and Day 14 measured pre-dose and up to 4 hours post-dose</time_frame>
        <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data, indicated by &quot;N&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 14</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1, which is taken as the maximum FEV1 recorded post-dose.</description>
          <population>The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data, indicated by &quot;N&quot;.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N=61, 68, 65, 71, 64, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" spread="83.02"/>
                    <measurement group_id="O2" value="109.6" spread="81.09"/>
                    <measurement group_id="O3" value="119.0" spread="81.64"/>
                    <measurement group_id="O4" value="116.2" spread="75.50"/>
                    <measurement group_id="O5" value="105.6" spread="70.64"/>
                    <measurement group_id="O6" value="90.5" spread="82.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 [N=61, 66, 64, 70, 62, 59]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="86.67"/>
                    <measurement group_id="O2" value="118.7" spread="88.42"/>
                    <measurement group_id="O3" value="96.7" spread="70.65"/>
                    <measurement group_id="O4" value="114.0" spread="76.41"/>
                    <measurement group_id="O5" value="114.6" spread="71.64"/>
                    <measurement group_id="O6" value="80.4" spread="76.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning and Evening Peak Expiratory Flow</title>
        <description>The Peak Expiratory Flow (PEF) rate is the maximal rate that a person can exhale during a short maximal expiratory effort after fully inhaling. Participants measured their PEF using a peak flow meter and recorded measurements in a diary every morning and evening during the study, prior to taking study medication. Change from baseline is the difference between the mean baseline PEF recorded during the screening period until the first day of treatment, and the overall mean PEF from Days 1 to 14.</description>
        <time_frame>Baseline (recorded during the screening period) and Days 1-14 (treatment period)</time_frame>
        <population>Intent to treat population. The analysis only includes patients with non-missing data, indicated by &quot;N&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning and Evening Peak Expiratory Flow</title>
          <description>The Peak Expiratory Flow (PEF) rate is the maximal rate that a person can exhale during a short maximal expiratory effort after fully inhaling. Participants measured their PEF using a peak flow meter and recorded measurements in a diary every morning and evening during the study, prior to taking study medication. Change from baseline is the difference between the mean baseline PEF recorded during the screening period until the first day of treatment, and the overall mean PEF from Days 1 to 14.</description>
          <population>Intent to treat population. The analysis only includes patients with non-missing data, indicated by &quot;N&quot;.</population>
          <units>liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning [N=56, 61, 53, 63, 57, 48]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="29.28"/>
                    <measurement group_id="O2" value="17.2" spread="34.07"/>
                    <measurement group_id="O3" value="25.7" spread="38.37"/>
                    <measurement group_id="O4" value="25.8" spread="47.36"/>
                    <measurement group_id="O5" value="25.2" spread="38.28"/>
                    <measurement group_id="O6" value="-4.3" spread="43.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening [N=56, 58, 54, 59, 55, 47]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="36.92"/>
                    <measurement group_id="O2" value="4.2" spread="37.82"/>
                    <measurement group_id="O3" value="18.4" spread="36.70"/>
                    <measurement group_id="O4" value="25.8" spread="38.07"/>
                    <measurement group_id="O5" value="26.2" spread="35.01"/>
                    <measurement group_id="O6" value="-11.4" spread="50.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using Rescue Medication</title>
        <description>Participants recorded the use of rescue medications (salbutamol/albuterol) for treatment of asthma symptoms twice a day in a diary during the 14 days of the treatment period.</description>
        <time_frame>Over 14 days</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 62.5 μg</title>
            <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 125 μg</title>
            <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 250 μg</title>
            <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Indacaterol 500 μg</title>
            <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Formoterol</title>
            <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using Rescue Medication</title>
          <description>Participants recorded the use of rescue medications (salbutamol/albuterol) for treatment of asthma symptoms twice a day in a diary during the 14 days of the treatment period.</description>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Night</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol 62.5 μg</title>
          <description>Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Indacaterol 125 μg</title>
          <description>Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>Indacaterol 250 μg</title>
          <description>Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="E4">
          <title>Indacaterol 500 μg</title>
          <description>Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
        <group group_id="E5">
          <title>Formoterol</title>
          <description>Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

